Treatment of cervicogenic headache with application of multicomponent bioregulation drug

Abstract

Introduction. According to the data of various authors Cervicogenic headache (CH) is met in 2.5 to 70% of population. Diagnostic criteria are described at The International classification of headache (3d revision). CH represents a heterogeneous group of headaches based on functional and organic changes of various anatomical structures of the cervical spine. There are no clinical recommendations for the treatment of patients with CH to date.The purpose of this clinical study is the assessment of the effectiveness of use of Traumeel® S in cervicogenic headache treatment.Materials and methods. 60 patients at the age from 18 to 45, divided into 3 groups were examined. Therapy in various combinations was applied to these patients of all the groups. The 2nd and the 3d groups were treated with the Traumeel® S local injection therapy. The patients of the 4th group were additionally given Traumeel® S in sublingual pill form. The visually analogue scale (VAS), the grading scale of the vertebral neurological symptoms, relapse rate of the CH during a year were applied.Results. The most effective treatment was observed in the 2nd group patients. This was manifested in Better dynamics of pain syndrome and the final result. The CH relapse rate during the year of patients treated with Traumeel® S was significantly lower.Conclusions. Traumeel® S inclusion into combined therapy of CH increases the effectiveness of treatment, helps reduce severity of pain, accelerate the appearance of positive therapeutic effect, operates to reduce severity of vertebral neurological symptoms, reduces frequency of recurrence.